NDA 022436 · Bausch
Xerese
Acyclovir, Hydrocortisone · Topical · Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor; Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor; Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor
Last checked: Nov 20, 2026Latest source record: Dec 11, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Jul 31, 2009
Approved uses
2
Original approval plus efficacy supplements
Registered trials
396
92 Phase 3, 31 recruiting
FAERS reports
40
24 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 3, 2020.
XERESE, a combination of acyclovir, a herpes simplex virus deoxynucleoside analog DNA polymerase inhibitor, and hydrocortisone, a corticosteroid, is indicated for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and children (6 years of age and older). XERESE, a combination of acyclovir, a herpes simplex virus deoxynucleoside analog DNA polymerase inhibitor, and hydrocortisone, a corticosteroid, is indicated for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and children (6 years of age and older). (1)
Mechanism: Acyclovir is an antiviral drug active against α-herpesviruses and hydrocortisone is an anti-inflammatory drug [see Microbiology (12.4) ].
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 22, 2014 Supplement 4 · Efficacy · priority review Pediatric Medical ReviewPediatric Clinical Pharmacology ReviewPediatric Statistical Review
- Jul 31, 2009 Original approval · Type 4 - New Combination Pediatric Medical ReviewLetterReview
1 products under this application
- XERESE · ACYCLOVIR 5%; HYDROCORTISONE 1% · CREAM, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Acyclovir" as an intervention, any sponsor and status, largest first.
- Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex LabialisPivotal-lookingCompleted
Padagis LLCIndustry
NCT02265913 · 4,076 participants · Start Oct 6, 2014 · Primary completion Apr 27, 2016
Drug: Acyclovir 5 percent (Perrigo); Acyclovir 5 percent (Reference) and 1 more · For: Herpes Labialis
Sites: Omaha, Nebraska
- A Study of Acyclovir to Help Prevent HIV Infection in People With Genital HerpesPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00076232 · 3,682 participants (planned) · Start Apr 2005 · Primary completion Jun 2007
Drug: Acyclovir; Acyclovir placebo · For: HIV Infections; HIV Seronegativity; Herpes Genitalis
Sites: San Francisco, California; New York, New York; Seattle, Washington
- Herpes Simplex Virus Type 2 (HSV-2) Suppression to Prevent HIV TransmissionPivotal-lookingCompleted
University of WashingtonAcademic, hospital or other
NCT00194519 · 3,408 participants · Start Nov 2004 · Primary completion Nov 2009
Drug: Generic acyclovir; Placebo · For: HIV Infection; Herpes Simplex, Genital; Sexually Transmitted Diseases
Sites: Gabarone, Botswana; Eldoret, Kenya; Kisumu, Kenya · 13 sites in all
- A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works NormallyPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT05098938 · 2,020 participants · Start Nov 23, 2021 · Primary completion Jul 19, 2023
Drug: Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773; Placebo · For: Recurrent Herpes Labialis
Sites: Culver City, California
- Phase 3 Clinical Study for the Treatment of Cold SorePivotal-lookingCompleted
Valerio TherapeuticsIndustry
NCT00769314 · 1,727 participants · Start May 2007 · Primary completion Nov 2008
Drug: Acyclovir Lauriad; Placebo · For: Herpes Labialis
Sites: Scottsdale, Arizona; Tucson, Arizona; San Francisco, California · 53 sites in all
- Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex LabialisPivotal-lookingCompleted
MedivirIndustry
NCT00361881 · 1,443 participants · Start Jul 2006 · Primary completion Aug 2007
Drug: ME-609; acyclovir in ME-609 vehicle and 1 more · For: Herpes Labialis
Sites: Mt. Pleasant, South Carolina
- A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected PatientsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00001038 · 1,200 participants · Primary completion May 1996
Drug: Valacyclovir hydrochloride; Acyclovir · For: Cytomegalovirus Infections; HIV Infections
Sites: Birmingham, Alabama; Los Angeles, California; Oakland, California · 35 sites in all
- Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital HerpesPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00306787 · 1,179 participants · Start Mar 2006 · Primary completion Feb 2008
Drug: Famciclovir; Valacyclovir and 2 more · For: Genital Herpes
Sites: Birmingham, Alabama; Chandler, Arizona; Phoenix, Arizona · 66 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pain11
- inflammation9
- oedema peripheral9
- pharyngeal paraesthesia9
- off label use4
- drug ineffective3
- herpes zoster3
- pain in extremity3
- application site pain2
- arthropathy2
- malaise2
- myocardial infarction2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 5 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 11 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xerese (Acyclovir/Hydrocortisone)
2024 spending
$577K
Beneficiaries
244
369 claims
Per beneficiary
$2,364
$243.36 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $513,363 |
| 2021 | $488,534 |
| 2022 | $452,625 |
| 2023 | $482,961 |
| 2024 | $576,763 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antiviral treatment for acute retinal necrosis: A systematic review and meta-analysis.
Putera I, Ridwan AS, Dewi M, et al. · Surv Ophthalmol 2024 · Meta-Analysis, Systematic Review
- Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis.
Barron BA, Gee L, Hauck WW, et al. · Ophthalmology 1994 · Clinical Trial, Multicenter Study
- Oral acyclovir in herpes zoster.
McKendrick MW, Care C, Burke C, et al. · J Antimicrob Chemother 1984 · Clinical Trial, Randomized Controlled Trial
- Acyclovir in shingles.
Bean B, Aeppli D, Balfour HH · J Antimicrob Chemother 1983 · Clinical Trial, Randomized Controlled Trial
- Acyclovir efficacy for bell's palsy treatment.
Günebakan Ç, Kuzu S, Bozkurt E · Am J Otolaryngol 2025 · Randomized Controlled Trial
- Intralesional acyclovir versus cryotherapy in treatment of plantar warts: A randomized controlled trial.
Azzazi Y, Helal B, Ramadan S · J Am Acad Dermatol 2026 · Randomized Controlled Trial, Comparative Study
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.